Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: February 27, 2026, 8:50 pm
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 500288 | NSE: MOREPENLAB

Morepen Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: February 27, 2026, 8:50 pm

Market Cap 2,390 Cr.
Current Price 43.7
Intrinsic Value₹62.71
High / Low 70.5/33.5
Stock P/E31.3
Book Value 21.8
Dividend Yield0.46 %
ROCE15.1 %
ROE11.8 %
Face Value 2.00
PEG Ratio-10.11

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Morepen Laboratories Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 120 Cr. 95.5 137/84.324.9 49.60.00 %12.9 %9.69 % 10.0
MPS Pharmaa Ltd 3.15 Cr. 1.65 3.69/1.60 0.330.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 3,359 Cr. 308 479/20870.3 24.30.22 %27.3 %21.7 % 1.00
Gujarat Terce Laboratories Ltd 29.9 Cr. 38.4 76.9/37.2 10.10.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 94.0 Cr. 64.2 64.7/17.0376 6.930.00 %13.5 %11.0 % 10.0
Industry Average20,545.80 Cr1,097.9755.88201.210.37%16.35%15.16%6.10

All Competitor Stocks of Morepen Laboratories Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 403348364401422445423455438453466425412
Expenses 374328348375388394375404394417424401381
Operating Profit 29211626345148524436422431
OPM % 7%6%4%7%8%11%11%11%10%8%9%6%7%
Other Income 11323443555430
Interest 0110021111544
Depreciation 7778881062516911
Profit before tax 22141121294442484635261646
Tax % 29%36%26%29%26%27%32%25%24%24%21%26%10%
Net Profit 169815213229363527201141
EPS in Rs 0.310.180.160.290.420.630.550.710.640.490.370.200.75

Last Updated: December 29, 2025, 10:35 pm

Below is a detailed analysis of the quarterly data for Morepen Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Sales, as of Sep 2025, the value is 412.00 Cr.. The value appears to be declining and may need further review. It has decreased from 425.00 Cr. (Jun 2025) to 412.00 Cr., marking a decrease of 13.00 Cr..
  • For Expenses, as of Sep 2025, the value is 381.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 401.00 Cr. (Jun 2025) to 381.00 Cr., marking a decrease of 20.00 Cr..
  • For Operating Profit, as of Sep 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Jun 2025) to 31.00 Cr., marking an increase of 7.00 Cr..
  • For OPM %, as of Sep 2025, the value is 7.00%. The value appears strong and on an upward trend. It has increased from 6.00% (Jun 2025) to 7.00%, marking an increase of 1.00%.
  • For Other Income, as of Sep 2025, the value is 30.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Jun 2025) to 30.00 Cr., marking an increase of 26.00 Cr..
  • For Interest, as of Sep 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 4.00 Cr..
  • For Depreciation, as of Sep 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.00 Cr. (Jun 2025) to 11.00 Cr., marking an increase of 2.00 Cr..
  • For Profit before tax, as of Sep 2025, the value is 46.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Jun 2025) to 46.00 Cr., marking an increase of 30.00 Cr..
  • For Tax %, as of Sep 2025, the value is 10.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Jun 2025) to 10.00%, marking a decrease of 16.00%.
  • For Net Profit, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Jun 2025) to 41.00 Cr., marking an increase of 30.00 Cr..
  • For EPS in Rs, as of Sep 2025, the value is 0.75. The value appears strong and on an upward trend. It has increased from 0.20 (Jun 2025) to 0.75, marking an increase of 0.55.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 2:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 3674014855956077698531,1881,5471,4181,6901,8121,787
Expenses 3183524245345427017851,0701,4101,3381,5321,6381,643
Operating Profit 4948626165686911913780159174143
OPM % 13%12%13%10%11%9%8%10%9%6%9%10%8%
Other Income 41-3444912106141843
Interest 1091084222-724817
Depreciation 46393534344037302828332947
Profit before tax -3213243029399912756135155122
Tax % 0%6%-1%0%0%1%14%1%20%31%29%24%
Net Profit -321324302934971023997118100
EPS in Rs -0.060.050.280.530.660.640.752.162.130.761.882.151.82
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%9%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)166.67%550.00%84.62%25.00%-3.33%17.24%185.29%5.15%-61.76%148.72%21.65%
Change in YoY Net Profit Growth (%)0.00%383.33%-465.38%-59.62%-28.33%20.57%168.05%-180.14%-66.92%210.48%-127.07%

Morepen Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: February 1, 2026, 1:05 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 909090909090909096102102110110
Reserves 8878911061361631943354836517451,0471,087
Borrowings 20920118716913413213317192529105158
Other Liabilities 103121156173226230246416473332417517381
Total Liabilities 4904895245385866156638581,0701,1101,2931,7781,736
Fixed Assets 368322297272264236216225252267307489471
CWIP 000000021417242826
Investments 0000001100185136
Other Assets 1211672272663213794466318048279601,1761,104
Total Assets 4904895245385866156638581,0701,1101,2931,7781,736

Below is a detailed analysis of the balance sheet data for Morepen Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 110.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 110.00 Cr..
  • For Reserves, as of Sep 2025, the value is 1,087.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,047.00 Cr. (Mar 2025) to 1,087.00 Cr., marking an increase of 40.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 158.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 105.00 Cr. (Mar 2025) to 158.00 Cr., marking an increase of 53.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 381.00 Cr.. The value appears to be improving (decreasing). It has decreased from 517.00 Cr. (Mar 2025) to 381.00 Cr., marking a decrease of 136.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 1,736.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,778.00 Cr. (Mar 2025) to 1,736.00 Cr., marking a decrease of 42.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 471.00 Cr.. The value appears to be declining and may need further review. It has decreased from 489.00 Cr. (Mar 2025) to 471.00 Cr., marking a decrease of 18.00 Cr..
  • For CWIP, as of Sep 2025, the value is 26.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Mar 2025) to 26.00 Cr., marking a decrease of 2.00 Cr..
  • For Investments, as of Sep 2025, the value is 136.00 Cr.. The value appears strong and on an upward trend. It has increased from 85.00 Cr. (Mar 2025) to 136.00 Cr., marking an increase of 51.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 1,104.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,176.00 Cr. (Mar 2025) to 1,104.00 Cr., marking a decrease of 72.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 1,736.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,778.00 Cr. (Mar 2025) to 1,736.00 Cr., marking a decrease of 42.00 Cr..

Notably, the Reserves (1,087.00 Cr.) exceed the Borrowings (158.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 3451504163171151-60-917332
Cash from Investing Activity + -1-32-27-14-27-13-12-70-32-47-83-322
Cash from Financing Activity + -29-19-27-24-38-0547661445300
Net Cash Flow 4-0-43-14428-266-510

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-160.00-153.00-125.00-108.00-69.00-64.00-64.00102.00118.0055.00130.0069.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 425166577364595659687065
Inventory Days 565551657669918296878594
Days Payable 116126140125173124113989087101114
Cash Conversion Cycle -17-20-23-3-249374065695445
Working Capital Days -21-20-10-86-62-34-817559894107
ROCE %1%3%8%9%9%8%10%23%23%8%17%15%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 38.22%38.22%38.22%38.22%38.22%38.22%35.66%35.66%35.66%35.66%35.66%35.66%
FIIs 0.96%1.00%1.29%2.11%1.85%1.67%2.08%2.22%1.94%1.72%1.62%1.62%
DIIs 2.93%2.32%2.27%2.21%2.15%2.14%1.69%1.64%1.67%1.50%1.49%1.25%
Government 0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public 57.88%58.45%58.20%57.46%57.76%57.96%60.57%60.46%60.72%61.09%61.22%61.46%
No. of Shareholders 3,06,1503,01,8323,04,0013,04,2893,36,0193,48,7664,30,9294,48,3614,68,8604,61,1804,61,8534,53,137

Shareholding Pattern Chart

No. of Shareholders

Morepen Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal BSE Healthcare ETF 4,401 0.16 0.024,4012025-04-22 16:00:160%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 2.201.880.772.262.16
Diluted EPS (Rs.) 2.201.880.771.962.16
Cash EPS (Rs.) 2.682.541.302.712.83
Book Value[Excl.RevalReserv]/Share (Rs.) 21.1016.5814.7212.109.43
Book Value[Incl.RevalReserv]/Share (Rs.) 21.1016.5814.7212.109.43
Revenue From Operations / Share (Rs.) 33.0633.0727.7332.3726.41
PBDIT / Share (Rs.) 3.513.381.683.082.90
PBIT / Share (Rs.) 2.982.721.132.502.23
PBT / Share (Rs.) 2.832.651.092.652.19
Net Profit / Share (Rs.) 2.151.890.752.132.16
NP After MI And SOA / Share (Rs.) 2.151.880.752.132.16
PBDIT Margin (%) 10.6210.216.049.5010.99
PBIT Margin (%) 9.028.234.077.718.44
PBT Margin (%) 8.568.013.938.198.29
Net Profit Margin (%) 6.515.712.726.578.17
NP After MI And SOA Margin (%) 6.515.682.726.578.17
Return on Networth / Equity (%) 10.2011.345.1317.5722.85
Return on Capital Employeed (%) 12.7915.617.3119.4422.07
Return On Assets (%) 6.637.433.489.5011.31
Long Term Debt / Equity (X) 0.020.000.000.000.00
Total Debt / Equity (X) 0.060.030.030.030.03
Asset Turnover Ratio (%) 1.181.411.301.601.47
Current Ratio (X) 2.322.212.351.611.30
Quick Ratio (X) 1.721.591.641.000.87
Inventory Turnover Ratio (X) 6.603.703.103.534.01
Interest Coverage Ratio (X) 23.0746.5243.25-19.9673.02
Interest Coverage Ratio (Post Tax) (X) 15.1527.0420.53-12.8155.29
Enterprise Value (Cr.) 2682.562126.721280.991720.861393.88
EV / Net Operating Revenue (X) 1.481.260.901.111.17
EV / EBITDA (X) 13.9412.3214.9511.7110.67
MarketCap / Net Operating Revenue (X) 1.451.270.921.131.22
Price / BV (X) 2.272.541.743.023.40
Price / Net Operating Revenue (X) 1.451.270.921.131.22
EarningsYield 0.040.040.020.050.06

After reviewing the key financial ratios for Morepen Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 2.20. This value is below the healthy minimum of 5. It has increased from 1.88 (Mar 24) to 2.20, marking an increase of 0.32.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 2.20. This value is below the healthy minimum of 5. It has increased from 1.88 (Mar 24) to 2.20, marking an increase of 0.32.
  • For Cash EPS (Rs.), as of Mar 25, the value is 2.68. This value is below the healthy minimum of 3. It has increased from 2.54 (Mar 24) to 2.68, marking an increase of 0.14.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 21.10. It has increased from 16.58 (Mar 24) to 21.10, marking an increase of 4.52.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 21.10. It has increased from 16.58 (Mar 24) to 21.10, marking an increase of 4.52.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 33.06. It has decreased from 33.07 (Mar 24) to 33.06, marking a decrease of 0.01.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 3.51. This value is within the healthy range. It has increased from 3.38 (Mar 24) to 3.51, marking an increase of 0.13.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 2.98. This value is within the healthy range. It has increased from 2.72 (Mar 24) to 2.98, marking an increase of 0.26.
  • For PBT / Share (Rs.), as of Mar 25, the value is 2.83. This value is within the healthy range. It has increased from 2.65 (Mar 24) to 2.83, marking an increase of 0.18.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from 1.89 (Mar 24) to 2.15, marking an increase of 0.26.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from 1.88 (Mar 24) to 2.15, marking an increase of 0.27.
  • For PBDIT Margin (%), as of Mar 25, the value is 10.62. This value is within the healthy range. It has increased from 10.21 (Mar 24) to 10.62, marking an increase of 0.41.
  • For PBIT Margin (%), as of Mar 25, the value is 9.02. This value is below the healthy minimum of 10. It has increased from 8.23 (Mar 24) to 9.02, marking an increase of 0.79.
  • For PBT Margin (%), as of Mar 25, the value is 8.56. This value is below the healthy minimum of 10. It has increased from 8.01 (Mar 24) to 8.56, marking an increase of 0.55.
  • For Net Profit Margin (%), as of Mar 25, the value is 6.51. This value is within the healthy range. It has increased from 5.71 (Mar 24) to 6.51, marking an increase of 0.80.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.51. This value is below the healthy minimum of 8. It has increased from 5.68 (Mar 24) to 6.51, marking an increase of 0.83.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 10.20. This value is below the healthy minimum of 15. It has decreased from 11.34 (Mar 24) to 10.20, marking a decrease of 1.14.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 12.79. This value is within the healthy range. It has decreased from 15.61 (Mar 24) to 12.79, marking a decrease of 2.82.
  • For Return On Assets (%), as of Mar 25, the value is 6.63. This value is within the healthy range. It has decreased from 7.43 (Mar 24) to 6.63, marking a decrease of 0.80.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has increased from 0.03 (Mar 24) to 0.06, marking an increase of 0.03.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 1.18. It has decreased from 1.41 (Mar 24) to 1.18, marking a decrease of 0.23.
  • For Current Ratio (X), as of Mar 25, the value is 2.32. This value is within the healthy range. It has increased from 2.21 (Mar 24) to 2.32, marking an increase of 0.11.
  • For Quick Ratio (X), as of Mar 25, the value is 1.72. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 1.72, marking an increase of 0.13.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.60. This value is within the healthy range. It has increased from 3.70 (Mar 24) to 6.60, marking an increase of 2.90.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 23.07. This value is within the healthy range. It has decreased from 46.52 (Mar 24) to 23.07, marking a decrease of 23.45.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 15.15. This value is within the healthy range. It has decreased from 27.04 (Mar 24) to 15.15, marking a decrease of 11.89.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 2,682.56. It has increased from 2,126.72 (Mar 24) to 2,682.56, marking an increase of 555.84.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 1.48, marking an increase of 0.22.
  • For EV / EBITDA (X), as of Mar 25, the value is 13.94. This value is within the healthy range. It has increased from 12.32 (Mar 24) to 13.94, marking an increase of 1.62.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 1.45, marking an increase of 0.18.
  • For Price / BV (X), as of Mar 25, the value is 2.27. This value is within the healthy range. It has decreased from 2.54 (Mar 24) to 2.27, marking a decrease of 0.27.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 1.45, marking an increase of 0.18.
  • For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Morepen Laboratories Ltd as of February 27, 2026 is: ₹64.71

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 27, 2026, Morepen Laboratories Ltd is Undervalued by 48.08% compared to the current share price ₹43.70

Intrinsic Value of Morepen Laboratories Ltd as of February 27, 2026 is: ₹62.71

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 27, 2026, Morepen Laboratories Ltd is Undervalued by 43.50% compared to the current share price ₹43.70

Last 5 Year EPS CAGR: -3.10%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a low average Working Capital Days of 10.83, which is a positive sign.
  2. The company has higher reserves (400.31 cr) compared to borrowings (116.77 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (314.08 cr) and profit (63.69 cr) over the years.
  1. The stock has a low average ROCE of 11.17%, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 19.33, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Morepen Laboratories Ltd:
    1. Net Profit Margin: 6.51%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 12.79% (Industry Average ROCE: 16.35%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 10.2% (Industry Average ROE: 15.16%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 15.15
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.72
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 31.3 (Industry average Stock P/E: 55.88)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.06
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Morepen Laboratories Ltd. is a Public Limited Listed company incorporated on 01/12/1984 and has its registered office in the State of Himachal Pradesh, India. Company's Corporate Identification Number(CIN) is L24231HP1984PLC006028 and registration number is 006028. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1554.54 Cr. and Equity Capital is Rs. 109.58 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsMorepen Village, Solan District Himachal Pradesh 173205Contact not found
Management
NamePosition Held
Mr. Sushil SuriChairman & Managing Director
Mr. Sanjay SuriWhole Time Director
Mr. Praveen Kumar DuttIndependent Director
Dr.(Mrs.) SavitaIndependent Director
Mr. Ranjit KhattarIndependent Director
Mr. Sharad JainIndependent Director

FAQ

What is the intrinsic value of Morepen Laboratories Ltd?

Morepen Laboratories Ltd's intrinsic value (as of 27 February 2026) is ₹62.71 which is 43.50% higher the current market price of ₹43.70, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹2,390 Cr. market cap, FY2025-2026 high/low of ₹70.5/33.5, reserves of ₹1,087 Cr, and liabilities of ₹1,736 Cr.

What is the Market Cap of Morepen Laboratories Ltd?

The Market Cap of Morepen Laboratories Ltd is 2,390 Cr..

What is the current Stock Price of Morepen Laboratories Ltd as on 27 February 2026?

The current stock price of Morepen Laboratories Ltd as on 27 February 2026 is ₹43.7.

What is the High / Low of Morepen Laboratories Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Morepen Laboratories Ltd stocks is ₹70.5/33.5.

What is the Stock P/E of Morepen Laboratories Ltd?

The Stock P/E of Morepen Laboratories Ltd is 31.3.

What is the Book Value of Morepen Laboratories Ltd?

The Book Value of Morepen Laboratories Ltd is 21.8.

What is the Dividend Yield of Morepen Laboratories Ltd?

The Dividend Yield of Morepen Laboratories Ltd is 0.46 %.

What is the ROCE of Morepen Laboratories Ltd?

The ROCE of Morepen Laboratories Ltd is 15.1 %.

What is the ROE of Morepen Laboratories Ltd?

The ROE of Morepen Laboratories Ltd is 11.8 %.

What is the Face Value of Morepen Laboratories Ltd?

The Face Value of Morepen Laboratories Ltd is 2.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Morepen Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports